Higher rates of AEs have been reported with VEGF/VEGFR therapies in Japanese or Asian patients with RCC [14, 15]; however, the safety and tolerability profiles were similar between this subgroup and the global study population, with balanced rates of TRAEs between the pembrolizumab–axitinib and sunitinib groups. This evidence concerns the gene VEGFA and renal cell carcinoma.